Summary of the published induction regimens for RS
| Reference . | Study design . | Patients . | RS type . | Regimen . | ORR,% . | CR,% . | PFS/ FFS, mo . | OS, mo . | Grade 3-4 . | TRM, % . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia,% . | Thrombocytopenia,% . | Infection,% . | ||||||||||
| 57 | Clinical trial | 26 | DLBCL | Hyper-CVXD | 41 | 38 | na | 10 | 100 | 79 | 50 | 14 |
| 56 | Clinical trial | 28 | DLBCL | DHAP, ESHAP | 43 | 25 | 1 | 8 | 83 | 82 | 43 | 18 |
| 58 | Clinical trial | 30 | DLBCL | R+hyper-CVXD+GM-CSF/R+HDM-ara-C+ GM-CSF | 43 | 38 | na | 8 | 100 | 40 | 39 | 22 |
| 54 | Clinical trial | 35 | DLBCL | OFAR1 | 50 | 20 | 3 | 8 | 85 | 95 | 8 | 3 |
| 55 | Clinical trial | 31 | DLBCL | OFAR2 | 38 | 6 | 3 | 6 | 89 | 77 | 17 | 8 |
| 52 | Clinical trial | 15 | DLBCL | R-CHOP | 67 | 7 | 10 | 21 | 55 | 65 | 28 | 3 |
| 53 | Clinical trial | 37 | DLBCL | CHOP-O | 46 | 27 | 6 | 11 | 33 | 25 | 51 | 0 |
| 63 | Clinical trial | 8 | DLBCL | Selinexor | 40 | 0 | na | na | na | na | na | na |
| 61 | Clinical trial | 29 | DLBCL | Acalabrutinib | 38 | 14 | 3 | na | 10 | na | na | na |
| 60 | Retrospective | 4 | DLBCL | Ibrutinib | 75 | 25 | na | na | na | na | na | na |
| 64 | Clinical trial | 9 | DLBCL | Pembrolizumab | 44 | 11 | 5.4 | 10.7 | na | na | na | na |
| 65 | Clinical trial | 3 | DLBCL | Nivolumab + ibrutinib | 50 | na | na | na | na | na | na | na |
| 62 | Clinical trial | 7 | DLBCL | Venetoclax | 43 | 0 | na | na | na | na | na | na |
| 43 | Retrospective | 46 | DLBCL | R-EPOCH | 37 | 20 | 3.5 | 5.9 | na | na | na | na |
| 69 | Retrospective | 18 | HL | ABVD (28%), CVPP (17%), CVPP/ABVD (5.5%), CHOP (5.5%), R-CHOP (5,5%), other (28%), no therapy (11%) | 44 | 17 | 5 | 10 | na | na | 6 | na |
| 71 | Retrospective | 16 | HL | ABVD (37.5%), MOPP + ABV (19%) BEACOPP (6%), Escalated BEACOPP (12%), ESHAP (6%), DVIP (12%), ABMT (6%) | na | 37 | na | 39.5 | na | na | na | na |
| 70 | Retrospective | 86 | HL | ABVD (31%), MOPP (16%), CHOP (13%), other (40%) | na | 27 | na | 19 | na | na | na | na |
| Reference . | Study design . | Patients . | RS type . | Regimen . | ORR,% . | CR,% . | PFS/ FFS, mo . | OS, mo . | Grade 3-4 . | TRM, % . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia,% . | Thrombocytopenia,% . | Infection,% . | ||||||||||
| 57 | Clinical trial | 26 | DLBCL | Hyper-CVXD | 41 | 38 | na | 10 | 100 | 79 | 50 | 14 |
| 56 | Clinical trial | 28 | DLBCL | DHAP, ESHAP | 43 | 25 | 1 | 8 | 83 | 82 | 43 | 18 |
| 58 | Clinical trial | 30 | DLBCL | R+hyper-CVXD+GM-CSF/R+HDM-ara-C+ GM-CSF | 43 | 38 | na | 8 | 100 | 40 | 39 | 22 |
| 54 | Clinical trial | 35 | DLBCL | OFAR1 | 50 | 20 | 3 | 8 | 85 | 95 | 8 | 3 |
| 55 | Clinical trial | 31 | DLBCL | OFAR2 | 38 | 6 | 3 | 6 | 89 | 77 | 17 | 8 |
| 52 | Clinical trial | 15 | DLBCL | R-CHOP | 67 | 7 | 10 | 21 | 55 | 65 | 28 | 3 |
| 53 | Clinical trial | 37 | DLBCL | CHOP-O | 46 | 27 | 6 | 11 | 33 | 25 | 51 | 0 |
| 63 | Clinical trial | 8 | DLBCL | Selinexor | 40 | 0 | na | na | na | na | na | na |
| 61 | Clinical trial | 29 | DLBCL | Acalabrutinib | 38 | 14 | 3 | na | 10 | na | na | na |
| 60 | Retrospective | 4 | DLBCL | Ibrutinib | 75 | 25 | na | na | na | na | na | na |
| 64 | Clinical trial | 9 | DLBCL | Pembrolizumab | 44 | 11 | 5.4 | 10.7 | na | na | na | na |
| 65 | Clinical trial | 3 | DLBCL | Nivolumab + ibrutinib | 50 | na | na | na | na | na | na | na |
| 62 | Clinical trial | 7 | DLBCL | Venetoclax | 43 | 0 | na | na | na | na | na | na |
| 43 | Retrospective | 46 | DLBCL | R-EPOCH | 37 | 20 | 3.5 | 5.9 | na | na | na | na |
| 69 | Retrospective | 18 | HL | ABVD (28%), CVPP (17%), CVPP/ABVD (5.5%), CHOP (5.5%), R-CHOP (5,5%), other (28%), no therapy (11%) | 44 | 17 | 5 | 10 | na | na | 6 | na |
| 71 | Retrospective | 16 | HL | ABVD (37.5%), MOPP + ABV (19%) BEACOPP (6%), Escalated BEACOPP (12%), ESHAP (6%), DVIP (12%), ABMT (6%) | na | 37 | na | 39.5 | na | na | na | na |
| 70 | Retrospective | 86 | HL | ABVD (31%), MOPP (16%), CHOP (13%), other (40%) | na | 27 | na | 19 | na | na | na | na |
ABMT, autologus bone marrow transplantation; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CHOP-O, CHOP plus ofatumumab; CR, complete response rate; CVPP, cyclophosphamide, vinblastine, procarbazine, and prednisone; DHAP, dexamethasone, cytarabine, and cisplatin; DVIP, dexamethasone, etoposide, ifosfamide, cisplatin; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; FFS, failure-free survival; GM-CSF, granulocyte macrophage–colony-stimulating factor; hyper-CVXD, fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone; MOPP, mechloretamine, vincristine, procarbazine, and prednisone; na, not available; OFAR, oxaliplatin, fluradabine, ara-C, and rituximab; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R+hyper-CVXD+GM-CSF/ R+HDM-ara-C+ GM-CSF, rituximab, fractionated cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone and GM-CSF alternating with rituximab, methotrexate, ara-C and GM-CSF; R-CHOP, rituximab, CHOP; R-EPOCH rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; TRM, treatment-related mortality.